{
  "meta": {
    "title": "31_Interleukins_Growth_Factors_And_Targeted_Therapies",
    "url": "https://brainandscalpel.vercel.app/31-interleukins-growth-factors-and-targeted-therapies-6bb1c0ba.html",
    "scrapedAt": "2025-11-30T06:59:52.072Z"
  },
  "questions": [
    {
      "id": 57845,
      "choices": [
        {
          "id": 258693,
          "text": "Osteosarcoma"
        },
        {
          "id": 258694,
          "text": "Prostate cancer"
        },
        {
          "id": 258695,
          "text": "ALL"
        },
        {
          "id": 258696,
          "text": "CML"
        }
      ],
      "text": "Aspariginase is given for treatment of?",
      "unique_key": "Q4923995",
      "question_audio": null,
      "question_video": null,
      "map_id": 34798066,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Acute Lymphoblastic Leukemia (ALL). Asparaginase is an enzyme that depletes asparagine, an essential amino acid required by rapidly dividing leukemic cells in ALL. Normal cells can synthesize asparagine, but ALL cells lack asparagine synthetase, making them dependent on extracellular sources. By breaking down circulating asparagine into aspartic acid and ammonia, asparaginase starves leukemic cells, leading to apoptosis and tumor regression. It is a key component of ALL chemotherapy regimens, often combined with vincristine, corticosteroids, and anthracyclines. Incorrect Options: (A) Osteosarcoma: Osteosarcoma is a bone tumor treated primarily with doxorubicin, cisplatin, methotrexate, and ifosfamide. Asparaginase has no role in its treatment, as osteosarcoma cells are not dependent on asparagine depletion. (B) Prostate Cancer: Prostate cancer is hormone-sensitive and primarily treated with androgen deprivation therapy (ADT), including GnRH agonists (leuprolide) or anti-androgens (bicalutamide). Asparaginase has no effect on prostate cancer progression. (D) Chronic Myeloid Leukemia (CML): CML is caused by the BCR-ABL fusion protein, making tyrosine kinase inhibitors (TKIs) like Imatinib the first-line treatment. Asparaginase does not target the molecular pathway of CML and is not used in its management.",
      "correct_choice_id": 258695,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19594841700318973/19594841700318973.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19594841700318973/19594841700318973.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57846,
      "choices": [
        {
          "id": 258697,
          "text": "Hydroxyurea"
        },
        {
          "id": 258698,
          "text": "Cisplatin"
        },
        {
          "id": 258699,
          "text": "Paclitaxel"
        },
        {
          "id": 258700,
          "text": "Carboplatin"
        }
      ],
      "text": "Which of the following drug is used for the treatment of sickle cell anemia",
      "unique_key": "Q3426934",
      "question_audio": null,
      "question_video": null,
      "map_id": 34281056,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hydroxyurea. Hydroxyurea is the mainstay treatment for sickle cell anemia, as it increases the production of fetal hemoglobin (HbF). Higher levels of HbF reduce the polymerization of sickle hemoglobin (HbS), thereby decreasing sickling of red blood cells (RBCs) and preventing vaso-occlusive crises. Hydroxyurea also improves red blood cell hydration, reduces inflammation, and lowers the risk of complications like pain crises, acute chest syndrome, and stroke. It has been shown to improve survival and quality of life in sickle cell patients. Incorrect Options: (B) Cisplatin: Cisplatin is a platinum-based chemotherapeutic agent used to treat solid tumors like testicular, ovarian, bladder, and lung cancers. It works by forming DNA cross-links, leading to apoptosis in cancer cells. However, it has no role in managing sickle cell anemia, as it does not affect HbS polymerization or RBC sickling. (C) Paclitaxel: Paclitaxel is a microtubule-stabilizing agent used in breast, ovarian, and lung cancers. It inhibits mitotic spindle function, leading to cell cycle arrest in rapidly dividing cancer cells. It does not influence hemoglobin production or RBC function and is not used in sickle cell anemia treatment. (D) Carboplatin: Like cisplatin, carboplatin is a platinum-based chemotherapy drug used for ovarian, lung, and other solid tumors. It works by damaging cancer cell DNA but does not impact HbF levels or sickling in sickle cell anemia.",
      "correct_choice_id": 258697,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66501211700318985/66501211700318985.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66501211700318985/66501211700318985.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57847,
      "choices": [
        {
          "id": 258701,
          "text": "Exerts antiplatelet, rather than thrombotic, effects"
        },
        {
          "id": 258702,
          "text": "Lacks ability to cause hot flashes or other disturbing side effects"
        },
        {
          "id": 258703,
          "text": "Lower risk of causing endometrial cancer"
        },
        {
          "id": 258704,
          "text": "Provides clinical cure, rather than palliation, in all patients"
        }
      ],
      "text": "a 42-yrs-old female , is diagnosed with metastatic breast cancer. Why might fulvestrant be the better choice over tamoxifen provided all other factors being equal?",
      "unique_key": "Q4265728",
      "question_audio": null,
      "question_video": null,
      "map_id": 34945471,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Lower risk of causing endometrial cancer. Fulvestrant is a selective estrogen receptor downregulator (SERD) that binds to estrogen receptors (ER) and promotes their degradation, leading to complete estrogen receptor blockade. Unlike Tamoxifen, which acts as a selective estrogen receptor modulator (SERM) and has estrogen agonist effects on the endometrium, Fulvestrant lacks any estrogenic activity. This means that Fulvestrant does not stimulate endometrial proliferation, making it a better choice in patients where the risk of endometrial hyperplasia or endometrial cancer is a concern. Incorrect Options: (A) Exerts antiplatelet, rather than thrombotic, effects: Neither Fulvestrant nor Tamoxifen has antiplatelet effects. In fact, Tamoxifen is associated with an increased risk of thromboembolism due to its partial estrogenic activity, particularly in the liver, where it increases clotting factor production. However, Fulvestrant does not significantly impact coagulation, but this is not the primary reason for its preference over Tamoxifen. (B) Lacks ability to cause hot flashes or other disturbing side effects: Fulvestrant can still cause hot flashes, as it completely blocks estrogen receptors, leading to menopausal-like symptoms. Both Fulvestrant and Tamoxifen are associated with side effects such as hot flashes, joint pain, and fatigue, making this statement incorrect. (D) Provides clinical cure, rather than palliation, in all patients: No hormonal therapy, including Fulvestrant, can guarantee a cure for metastatic breast cancer. These treatments are primarily palliative, aiming to slow disease progression and improve quality of life rather than completely eradicating the cancer.",
      "correct_choice_id": 258703,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15208641700319163/15208641700319163.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15208641700319163/15208641700319163.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57848,
      "choices": [
        {
          "id": 258705,
          "text": "Folinic acid and vitamin B6"
        },
        {
          "id": 258706,
          "text": "Folic acid and vitamin B12"
        },
        {
          "id": 258707,
          "text": "Vitamin B6 and Vitamin B12"
        },
        {
          "id": 258708,
          "text": "Folic acid and dexamethasone"
        }
      ],
      "text": "Which of the following medications is essential for ameliorating the toxicity of pemetrexed? (AIIMS May 2014)",
      "unique_key": "Q2879793",
      "question_audio": null,
      "question_video": null,
      "map_id": 34519192,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Folic acid and vitamin B12 are essential for ameliorating the toxicity of pemetrexed Pemetrexed toxicity resembles that of methotrexate ( both are folic acid pathway inhibitor), with the additional feature of a prominent erythematous and puritic rash in 40% of patients. Severe myelosuppression with pemetrexed, seen especially in patients with pre-existing homocystinemia and possibly reflecting, folate deficiency, is largely eliminated by concurrent administration of low dosages of folic acid beginning 1-2 weeks prior to pemetrexed and continuing while the drug is administered. Patients should receive intramuscular vitamin B12 with the first dose of pemetrexed to correct possible B12 deficiency.",
      "correct_choice_id": 258706,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71582871700319352/71582871700319352.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71582871700319352/71582871700319352.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57849,
      "choices": [
        {
          "id": 258709,
          "text": "Metabolised by cytochrome p450 enzymes"
        },
        {
          "id": 258710,
          "text": "Less neurotoxic than cyclophosphamide"
        },
        {
          "id": 258711,
          "text": "Chloracetaldehyde is the metabolite of ifosfamide"
        },
        {
          "id": 258712,
          "text": "It is a nitrogen mustard"
        }
      ],
      "text": "All of the following are true regarding ifosfamide except:",
      "unique_key": "Q4177053",
      "question_audio": null,
      "question_video": null,
      "map_id": 34737954,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Ifosfamide is a nitrogen mustard which is more potent and neurotoxic than cyclophosphamide These are given as prodrugs and metabolized by cytochrome p450 enzymes. Ifosfamide produces chloracetaldehyde and acrolein as metabolites, Acrolein results in hemorrhagic cystitits whereas chloracetaldehyde is responsible for nephrotoxicity. Ifosfamide has same toxicity profile as cyclophosphamide although it causes more platelet suppression, neurotoxicity, nephrotoxicity and hemorrhagic cystitis due to its high potency",
      "correct_choice_id": 258710,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72472971700319364/72472971700319364.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72472971700319364/72472971700319364.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57850,
      "choices": [
        {
          "id": 258713,
          "text": "Sturge-Weber syndrome"
        },
        {
          "id": 258714,
          "text": "Laryngotracheal stenosis"
        },
        {
          "id": 258715,
          "text": "Endoscopic angiofiroma"
        },
        {
          "id": 258716,
          "text": "Skull base osteomyelitis"
        }
      ],
      "text": "Topical mitomycin-C is used in :",
      "unique_key": "Q3739215",
      "question_audio": null,
      "question_video": null,
      "map_id": 34000075,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Laryngotracheal stenosis. Mitomycin-C is an antineoplastic antibiotic that inhibits DNA synthesis and fibroblast proliferation, preventing scar formation. It is used topically to reduce the risk of restenosis following laryngotracheal reconstruction or endoscopic dilation procedures. By inhibiting fibroblasts and excessive scarring, mitomycin-C helps maintain airway patency, making it a valuable adjunct in treating laryngotracheal stenosis. Incorrect Options: (A) Sturge-Weber syndrome: Sturge-Weber syndrome is a neurocutaneous disorder characterized by a facial port-wine stain, leptomeningeal angiomatosis, and glaucoma. Mitomycin-C does not play a role in its management, which mainly involves laser therapy for the port-wine stain, antiepileptic drugs for seizures, and glaucoma treatment. (C) Endoscopic angiofibroma: Juvenile nasopharyngeal angiofibroma (JNA) is a vascular tumor occurring in adolescent males. Treatment typically involves surgical excision, often preceded by embolization to reduce bleeding. Mitomycin-C does not have a role in JNA management, as it does not target vascular tumors or reduce tumor growth. (D) Skull base osteomyelitis: This is a severe infection of the skull base, often seen in diabetics and immunocompromised patients, usually caused by Pseudomonas aeruginosa. Treatment requires long-term intravenous antibiotics and sometimes surgical debridement. Mitomycin-C has no role in the treatment of skull base osteomyelitis.",
      "correct_choice_id": 258714,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31493631700319388/31493631700319388.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31493631700319388/31493631700319388.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57851,
      "choices": [
        {
          "id": 258717,
          "text": "Acute promyelocytic leukemia"
        },
        {
          "id": 258718,
          "text": "A.L.L."
        },
        {
          "id": 258719,
          "text": "CML"
        },
        {
          "id": 258720,
          "text": "Transient myeloproliferative disorder"
        }
      ],
      "text": "All-trans-retinoic acid is used in treatment of :",
      "unique_key": "Q3775143",
      "question_audio": null,
      "question_video": null,
      "map_id": 34271491,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Acute promyelocytic leukemia (APL). All-trans-retinoic acid (ATRA) is the standard treatment for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML) with the t(15;17) translocation. This translocation leads to the formation of the PML-RARA fusion gene, which blocks the differentiation of promyelocytes. ATRA works by binding to the altered retinoic acid receptor (RARA), promoting differentiation of the immature promyelocytes into mature myeloid cells, thereby reducing the leukemic burden. It is often combined with arsenic trioxide or chemotherapy to improve outcomes and reduce relapse rates. Incorrect Options: (B) Acute Lymphoblastic Leukemia (ALL): ALL is a lymphoid malignancy, not a myeloid disorder, and is treated with chemotherapy regimens including vincristine, corticosteroids, asparaginase, and methotrexate. ATRA has no role in ALL treatment, as this disease does not involve the PML-RARA fusion gene. (C) Chronic Myeloid Leukemia (CML): CML is characterized by the BCR-ABL fusion gene (Philadelphia chromosome), which leads to increased tyrosine kinase activity. It is treated with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib, rather than ATRA. (D) Transient Myeloproliferative Disorder (TMD): TMD is a self-limiting myeloproliferative condition seen in newborns with Down syndrome. It usually resolves on its own, though some cases may progress to acute megakaryoblastic leukemia (AML M7). ATRA is not used in TMD treatment, as it is specific for APL.",
      "correct_choice_id": 258717,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2222041700319449/2222041700319449.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2222041700319449/2222041700319449.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57852,
      "choices": [
        {
          "id": 258721,
          "text": "5-FU"
        },
        {
          "id": 258722,
          "text": "L-asparaginase"
        },
        {
          "id": 258723,
          "text": "Melphatan"
        },
        {
          "id": 258724,
          "text": "Carmustine"
        }
      ],
      "text": "Which of the following anticancer drugs can cause hypercoagulable state:",
      "unique_key": "Q4815323",
      "question_audio": null,
      "question_video": null,
      "map_id": 34524266,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) L-asparaginase. L-asparaginase is an enzyme used primarily in the treatment of acute lymphoblastic leukemia (ALL). It works by depleting asparagine, an essential amino acid for leukemia cells, leading to protein synthesis inhibition and apoptosis. However, one of its major side effects is induction of a hypercoagulable state, increasing the risk of thrombosis. This occurs due to its suppression of protein C, protein S, and antithrombin III, which are natural anticoagulants. As a result, patients receiving L-asparaginase therapy are at high risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Incorrect Options: (A) 5-Fluorouracil (5-FU): 5-FU is a pyrimidine analog that inhibits thymidylate synthase, impairing DNA synthesis. It is used in colorectal, breast, and other cancers. While 5-FU can cause cardiotoxicity (coronary vasospasm) and myelosuppression, it does not significantly induce a hypercoagulable state. (C) Melphalan: Melphalan is an alkylating agent used in multiple myeloma and ovarian cancer. It can cause myelosuppression and mucositis, but it is not associated with increased thrombosis risk. (D) Carmustine: Carmustine is a nitrosourea alkylating agent used in brain tumors and lymphomas. It is associated with bone marrow suppression and pulmonary fibrosis, but not with a hypercoagulable state.",
      "correct_choice_id": 258722,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29699961700319470/29699961700319470.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29699961700319470/29699961700319470.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57853,
      "choices": [
        {
          "id": 258725,
          "text": "Chlorambucil"
        },
        {
          "id": 258726,
          "text": "Daunorubicin"
        },
        {
          "id": 258727,
          "text": "Doxorubicin"
        },
        {
          "id": 258728,
          "text": "Flutamide"
        }
      ],
      "text": "All of the following anticancer agents cause bone marrow suppression except:",
      "unique_key": "Q8838653",
      "question_audio": null,
      "question_video": null,
      "map_id": 34811924,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Flutamide. Flutamide is a non-steroidal anti-androgen used in the treatment of prostate cancer. It works by competitively inhibiting androgen receptors, preventing testosterone from stimulating prostate cancer growth. Since it primarily affects hormonal pathways, it does not cause significant bone marrow suppression, unlike traditional cytotoxic chemotherapy drugs. Its major side effects include hepatotoxicity, gynecomastia, and gastrointestinal disturbances, but not myelosuppression. Incorrect Options: (A) Chlorambucil: Chlorambucil is an alkylating agent used in chronic lymphocytic leukemia (CLL) and lymphomas. Like other alkylating agents, it affects rapidly dividing cells, leading to bone marrow suppression, neutropenia, and anemia. (B) Daunorubicin: Daunorubicin is an anthracycline antibiotic used in acute leukemias (ALL and AML). It inhibits topoisomerase II, causing DNA damage and apoptosis. Myelosuppression is a major dose-limiting toxicity, along with cardiotoxicity. (C) Doxorubicin: Like daunorubicin, doxorubicin is also an anthracycline, used in breast cancer, lymphomas, and sarcomas. It also inhibits topoisomerase II, leading to bone marrow suppression and cardiotoxicity.",
      "correct_choice_id": 258728,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18211481700319482/18211481700319482.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18211481700319482/18211481700319482.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57854,
      "choices": [
        {
          "id": 258729,
          "text": "melphalan"
        },
        {
          "id": 258730,
          "text": "ifosfamide"
        },
        {
          "id": 258731,
          "text": "mechlorethamine"
        },
        {
          "id": 258732,
          "text": "procarbazine"
        }
      ],
      "text": "which of the following is given by local route for treatment of cutaneous T cell lymphoma?",
      "unique_key": "Q7195931",
      "question_audio": null,
      "question_video": null,
      "map_id": 34473058,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Mechlorethamine. Mechlorethamine, also known as nitrogen mustard, is an alkylating agent that works by cross-linking DNA, leading to cell cycle arrest and apoptosis. It is used topically in the treatment of cutaneous T-cell lymphoma (CTCL), particularly in mycosis fungoides, to target malignant T-cells locally and reduce systemic toxicity. Incorrect Options: (A) Melphalan – Incorrect Melphalan is an alkylating agent but is not used topically for cutaneous T-cell lymphoma. It is mainly administered orally or intravenously for conditions such as multiple myeloma and ovarian cancer. (B) Ifosfamide – Incorrect Ifosfamide is an alkylating agent related to cyclophosphamide but is administered intravenously (IV) and is not used locally for CTCL. It is commonly used for sarcomas, testicular cancer, and lymphomas. (D) Procarbazine – Incorrect Procarbazine is an oral alkylating agent used primarily for Hodgkin’s lymphoma and brain tumors. It is not used topically for CTCL.",
      "correct_choice_id": 258731,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75751301700319556/75751301700319556.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75751301700319556/75751301700319556.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57855,
      "choices": [
        {
          "id": 258733,
          "text": "Vancomycin"
        },
        {
          "id": 258734,
          "text": "Actinomycin-D"
        },
        {
          "id": 258735,
          "text": "Busulfan"
        },
        {
          "id": 258736,
          "text": "Vincristine"
        }
      ],
      "text": "Which of the following drugs is an anticancer antibiotic :",
      "unique_key": "Q4872636",
      "question_audio": null,
      "question_video": null,
      "map_id": 34497011,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Actinomycin-D. Actinomycin-D (Dactinomycin) is an anticancer antibiotic that exerts its effect by intercalating into DNA and inhibiting RNA synthesis, leading to apoptosis of rapidly dividing cancer cells. It is used in the treatment of Wilms tumor, rhabdomyosarcoma, Ewing’s sarcoma, and gestational trophoblastic neoplasia. Incorrect Options: (A) Vancomycin – Incorrect Vancomycin is an antibiotic but is not an anticancer drug. It is primarily used to treat Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections. (C) Busulfan – Incorrect Busulfan is an alkylating agent, not an antibiotic. It is commonly used in the treatment of chronic myeloid leukemia (CML) and as a conditioning regimen before bone marrow transplantation. (D) Vincristine – Incorrect Vincristine is a vinca alkaloid, not an antibiotic. It inhibits microtubule formation, disrupting mitosis, and is used for leukemias, lymphomas, and solid tumors.",
      "correct_choice_id": 258734,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11396531700319585/11396531700319585.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11396531700319585/11396531700319585.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57856,
      "choices": [
        {
          "id": 258737,
          "text": "Colony stimulating factor"
        },
        {
          "id": 258738,
          "text": "Amifostine"
        },
        {
          "id": 258739,
          "text": "Cisplatin"
        },
        {
          "id": 258740,
          "text": "Methotrexate"
        }
      ],
      "text": "Which of the following is a radioprotector:",
      "unique_key": "Q6761150",
      "question_audio": null,
      "question_video": null,
      "map_id": 34000568,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Amifostine. Amifostine is a well-known radioprotective agent used to reduce the harmful effects of radiation therapy, particularly in normal tissues. It acts as a free radical scavenger, preventing DNA damage in healthy cells while allowing radiation to exert its cytotoxic effects on cancerous tissues. It is commonly used to reduce xerostomia (dry mouth) in patients undergoing radiation therapy for head and neck cancers and to protect against cisplatin-induced nephrotoxicity. Incorrect Options: (A) Colony Stimulating Factor – Incorrect Colony-stimulating factors (CSFs), such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), are used to stimulate the production of white blood cells after chemotherapy or radiation-induced myelosuppression. While they help in managing radiation-induced neutropenia, they do not directly act as radioprotectors by preventing DNA damage. (C) Cisplatin – Incorrect Cisplatin is a platinum-based chemotherapeutic agent that causes DNA cross-linking, leading to apoptosis in rapidly dividing cancer cells. Instead of protecting against radiation, it actually enhances the cytotoxic effects of radiation therapy (radiosensitizer), making it not a radioprotector but a radiosensitizer. (D) Methotrexate – Incorrect Methotrexate is an antimetabolite and antifolate chemotherapeutic agent that inhibits dihydrofolate reductase (DHFR), leading to decreased DNA synthesis. It does not have radioprotective properties; rather, it may increase the sensitivity of cancer cells to radiation.",
      "correct_choice_id": 258738,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8849371700319636/8849371700319636.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8849371700319636/8849371700319636.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57857,
      "choices": [
        {
          "id": 258741,
          "text": "HIV associated peripheral neuropathy"
        },
        {
          "id": 258742,
          "text": "HIV associated aphthous (mouth) ulcers"
        },
        {
          "id": 258743,
          "text": "Bhecet syndrome"
        },
        {
          "id": 258744,
          "text": "Erythema nodosum leprosum"
        }
      ],
      "text": "Thalidomide is used in all of the following except:",
      "unique_key": "Q8784411",
      "question_audio": null,
      "question_video": null,
      "map_id": 34622623,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) HIV-associated peripheral neuropathy. Thalidomide is not used for HIV-associated peripheral neuropathy because it has neurotoxic properties and can actually worsen neuropathy. Since thalidomide affects nerve function, its use in conditions like peripheral neuropathy is contraindicated due to the risk of exacerbating symptoms such as numbness, tingling, and pain. Incorrect Options: (B) HIV-associated aphthous (mouth) ulcers – Incorrect Thalidomide is used for refractory HIV-associated aphthous ulcers due to its immunomodulatory and anti-inflammatory effects. It helps reduce inflammation and promotes healing, making it an effective treatment option for severe cases that do not respond to conventional therapies. (C) Behçet syndrome – Incorrect Behçet syndrome is a chronic inflammatory disorder that leads to recurrent oral and genital ulcers, uveitis, and vasculitis. Thalidomide has been shown to reduce inflammation and ulcer recurrence, making it beneficial in the management of Behçet syndrome, particularly in patients who are unresponsive to other treatments. (D) Erythema nodosum leprosum – Incorrect Erythema nodosum leprosum (ENL) is a severe inflammatory complication of leprosy characterized by painful nodules and systemic inflammation. Thalidomide is a first-line treatment for ENL, as it significantly reduces inflammation and provides symptomatic relief by modulating the immune response.",
      "correct_choice_id": 258741,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28007791700319653/28007791700319653.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28007791700319653/28007791700319653.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57858,
      "choices": [
        {
          "id": 258745,
          "text": "Associated with diarrhea"
        },
        {
          "id": 258746,
          "text": "Characterized by enantiomeric inter conversions"
        },
        {
          "id": 258747,
          "text": "Metabolized extensively by hepatic CYP system"
        },
        {
          "id": 258748,
          "text": "Safe for use in pregnant females"
        }
      ],
      "text": "Thalidomide, used for multiple myeloma, is :",
      "unique_key": "Q2417282",
      "question_audio": null,
      "question_video": null,
      "map_id": 34658431,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Characterized by enantiomeric interconversions. Thalidomide exists as a racemic mixture of R- and S-enantiomers, which can interconvert in vivo. The R-enantiomer has sedative effects, whereas the S-enantiomer is teratogenic and responsible for its notorious birth defects. Due to this interconversion, isolating one enantiomer does not prevent its transformation into the other inside the body, making strict regulation necessary. Thalidomide is now used mainly in multiple myeloma and erythema nodosum leprosum, with close monitoring. Incorrect Options: (A) Associated with diarrhea – Incorrect Thalidomide is not commonly associated with diarrhea. Instead, it frequently causes constipation, sedation, peripheral neuropathy, and thromboembolism. (C) Metabolized extensively by hepatic CYP system – Incorrect Unlike many drugs, thalidomide is not primarily metabolized by hepatic cytochrome P450 enzymes. Instead, it undergoes non-enzymatic hydrolysis in plasma and tissues, leading to multiple inactive metabolites. (D) Safe for use in pregnant females – Incorrect Thalidomide is highly teratogenic and is strictly contraindicated in pregnancy. It was originally used as a sedative and anti-nausea drug in pregnant women in the 1950s and 1960s, leading to severe birth defects (phocomelia, limb deformities). Due to this, it is only prescribed under strict regulatory programs such as the Thalidomide Risk Evaluation and Mitigation Strategy (REMS).",
      "correct_choice_id": 258746,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1786031700319696/1786031700319696.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1786031700319696/1786031700319696.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57859,
      "choices": [
        {
          "id": 258749,
          "text": "Ganirelix"
        },
        {
          "id": 258750,
          "text": "Cetrorelix"
        },
        {
          "id": 258751,
          "text": "Abarelix"
        },
        {
          "id": 258752,
          "text": "Goserelin"
        }
      ],
      "text": "Which of the following drugs is useful for the treatment of advanced prostate cancer:",
      "unique_key": "Q5179532",
      "question_audio": null,
      "question_video": null,
      "map_id": 34391844,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Goserelin. Goserelin is a gonadotropin-releasing hormone (GnRH) agonist that is used in the treatment of advanced prostate cancer. It works by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient increase in testosterone levels. However, with continuous administration, GnRH receptors become desensitized, causing a suppression of LH and FSH release, ultimately leading to testosterone suppression. Since prostate cancer growth is often driven by androgens, reducing testosterone levels helps slow disease progression. Incorrect Options: (A) Ganirelix – Incorrect Ganirelix is a GnRH antagonist that is primarily used in assisted reproductive technology (ART) to prevent premature ovulation. It does not have a significant role in the treatment of advanced prostate cancer. (B) Cetrorelix – Incorrect Like Ganirelix, Cetrorelix is also a GnRH antagonist, mainly used in fertility treatments rather than in prostate cancer therapy. It does not achieve long-term testosterone suppression, which is necessary for treating hormone-sensitive prostate cancer. (C) Abarelix – Incorrect Abarelix is a GnRH antagonist that can suppress testosterone levels without the initial flare effect seen with GnRH agonists like Goserelin. However, it is less commonly used than degarelix, another GnRH antagonist, and has been associated with severe allergic reactions, limiting its clinical use.",
      "correct_choice_id": 258752,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59402071700319744/59402071700319744.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59402071700319744/59402071700319744.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57860,
      "choices": [
        {
          "id": 258753,
          "text": "Mitomycin C"
        },
        {
          "id": 258754,
          "text": "Doxorubicin"
        },
        {
          "id": 258755,
          "text": "Bleomycin"
        },
        {
          "id": 258756,
          "text": "Clindamycin"
        }
      ],
      "text": "Drug locally used for tracheal stenosis is:",
      "unique_key": "Q7656346",
      "question_audio": null,
      "question_video": null,
      "map_id": 34486981,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Mitomycin C. Mitomycin C is an antineoplastic antibiotic that is used locally to prevent fibroblast proliferation and scar formation. It is commonly applied topically during surgical or endoscopic procedures to reduce postoperative fibrosis and restenosis in conditions such as tracheal stenosis. It works by inhibiting DNA synthesis, thereby reducing the excessive healing response that leads to scar formation and airway narrowing. Incorrect Options: (B) Doxorubicin – Incorrect Doxorubicin is an anthracycline antibiotic used in systemic chemotherapy for various cancers. It is not applied locally for tracheal stenosis as it does not specifically prevent fibroblast proliferation or scar formation in the airway. (C) Bleomycin – Incorrect Bleomycin is a chemotherapeutic agent known for its use in treating various cancers, including Hodgkin's lymphoma and testicular cancer. It is also associated with pulmonary fibrosis as a side effect, making it unsuitable for treating tracheal stenosis. (D) Clindamycin – Incorrect Clindamycin is an antibiotic used for treating bacterial infections, particularly anaerobic infections and respiratory tract infections. It does not have antifibrotic properties and is not used in the management of tracheal stenosis.",
      "correct_choice_id": 258753,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17787141700319756/17787141700319756.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17787141700319756/17787141700319756.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57861,
      "choices": [
        {
          "id": 258757,
          "text": "High dose methotrexate"
        },
        {
          "id": 258758,
          "text": "High dose cytarabine"
        },
        {
          "id": 258759,
          "text": "Cladribine"
        },
        {
          "id": 258760,
          "text": "Fludarabine"
        }
      ],
      "text": "Which of the following drugs is used for the treatment of refractory histiocytosis:",
      "unique_key": "Q3259017",
      "question_audio": null,
      "question_video": null,
      "map_id": 34967858,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Cladribine. Cladribine is a purine analog that selectively targets monocytes and lymphocytes, making it effective for histiocytic disorders, including refractory Langerhans cell histiocytosis (LCH). It is a prodrug that gets incorporated into DNA, leading to strand breaks and apoptosis in affected cells. Cladribine is particularly useful for cases that are unresponsive to conventional treatments, offering a viable option for refractory histiocytosis. Incorrect Options: (A) High-dose methotrexate – Incorrect Methotrexate is a folate antagonist used for treating leukemias, lymphomas, and autoimmune disorders. It does not have a primary role in treating histiocytosis, especially refractory cases. (B) High-dose cytarabine – Incorrect Cytarabine is a pyrimidine analog primarily used in acute myeloid leukemia (AML) and lymphomas. Though it affects rapidly dividing cells, it is not the first-line or most effective treatment for refractory histiocytosis. (D) Fludarabine – Incorrect Fludarabine is another purine analog used in chronic lymphocytic leukemia (CLL) and low-grade lymphomas. While it has immunosuppressive properties, Cladribine has shown superior efficacy in histiocytic disorders.",
      "correct_choice_id": 258759,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61916561700319767/61916561700319767.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61916561700319767/61916561700319767.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57862,
      "choices": [
        {
          "id": 258761,
          "text": "Gastrointestinal toxicity"
        },
        {
          "id": 258762,
          "text": "Neurotoxicity"
        },
        {
          "id": 258763,
          "text": "Bone marrow suppression"
        },
        {
          "id": 258764,
          "text": "Nephrotoxicity"
        }
      ],
      "text": "Most important dose-limiting toxicity of cancer chemotherapy is :",
      "unique_key": "Q1411833",
      "question_audio": null,
      "question_video": null,
      "map_id": 34932083,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Bone marrow suppression. The most important dose-limiting toxicity of cancer chemotherapy is myelosuppression, which affects rapidly dividing hematopoietic cells in the bone marrow. This leads to leukopenia (increased risk of infections), thrombocytopenia (increased bleeding tendency), and anemia (fatigue and weakness). Since most chemotherapeutic agents target rapidly dividing cells, the bone marrow is highly susceptible to damage, and the extent of suppression often determines dose adjustments and treatment schedules. Drugs such as alkylating agents (cyclophosphamide), antimetabolites (methotrexate, 5-FU), and anthracyclines (doxorubicin) are commonly associated with myelosuppression. Incorrect Options: (A) Gastrointestinal toxicity – Incorrect While nausea, vomiting, and mucositis are common side effects of chemotherapy, they are not usually dose-limiting. Antiemetics (ondansetron) and supportive care can help manage these toxicities. However, severe diarrhea due to agents like irinotecan or mucositis from methotrexate can occasionally impact dosing but are not the primary dose-limiting factors. (B) Neurotoxicity – Incorrect Neurotoxicity occurs with agents like vincristine (peripheral neuropathy) and cisplatin (ototoxicity and neuropathy), but it is not the most common dose-limiting toxicity. Neuropathy often accumulates over multiple cycles but does not universally limit dosing like bone marrow suppression does. (D) Nephrotoxicity – Incorrect Kidney damage is seen with drugs like cisplatin, methotrexate (high-dose), and ifosfamide, but it is not the most frequent reason for dose limitation. Hydration, dose adjustments, and nephroprotective agents (e.g., amifostine with cisplatin) can mitigate nephrotoxicity.",
      "correct_choice_id": 258763,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43377691700319811/43377691700319811.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43377691700319811/43377691700319811.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57863,
      "choices": [
        {
          "id": 258765,
          "text": "Mechlorethamine"
        },
        {
          "id": 258766,
          "text": "Paclitaxel"
        },
        {
          "id": 258767,
          "text": "Etoposide"
        },
        {
          "id": 258768,
          "text": "Mitoxantrone"
        }
      ],
      "text": "“Stocking and glove” neuropathy is seen in :",
      "unique_key": "Q8370258",
      "question_audio": null,
      "question_video": null,
      "map_id": 34576113,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Paclitaxel. Paclitaxel is a microtubule-stabilizing agent belonging to the taxane class, commonly used in the treatment of breast cancer, ovarian cancer, and non-small cell lung cancer. One of its most well-known toxicities is peripheral neuropathy, which manifests as a \"stocking and glove\" neuropathy. This condition is characterized by numbness, tingling, and burning sensations in the hands and feet, following a length-dependent pattern of nerve damage. The neuropathy is dose-dependent and results from the drug’s interference with axonal transport and microtubule function in neurons. Incorrect Options (True Statements): (A) Mechlorethamine – Incorrect Mechlorethamine is a nitrogen mustard alkylating agent primarily used for Hodgkin’s lymphoma. While it can cause myelosuppression and nausea, it is not associated with peripheral neuropathy, making it an incorrect choice. (C) Etoposide – Incorrect Etoposide is a topoisomerase II inhibitor used in lung cancer, testicular cancer, and hematologic malignancies. Its primary toxicities include myelosuppression and secondary leukemias rather than significant peripheral neuropathy. (D) Mitoxantrone – Incorrect Mitoxantrone is an anthracenedione chemotherapeutic agent used in breast cancer, leukemia, and multiple sclerosis. It is primarily associated with cardiotoxicity rather than neurotoxicity.",
      "correct_choice_id": 258766,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49522051700319943/49522051700319943.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49522051700319943/49522051700319943.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57864,
      "choices": [
        {
          "id": 258769,
          "text": "Methotrexate"
        },
        {
          "id": 258770,
          "text": "Actinomycin-D"
        },
        {
          "id": 258771,
          "text": "Vincristine"
        },
        {
          "id": 258772,
          "text": "6-Thioguanine"
        }
      ],
      "text": "The drug of choice in choriocarcinoma is:",
      "unique_key": "Q3710834",
      "question_audio": null,
      "question_video": null,
      "map_id": 34444354,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Methotrexate. Methotrexate (MTX) is the drug of choice for choriocarcinoma, a highly malignant gestational trophoblastic neoplasm (GTN). It is a folate antagonist that inhibits dihydrofolate reductase (DHFR), preventing the synthesis of tetrahydrofolate, which is essential for DNA and RNA synthesis. This leads to cell cycle arrest in the S-phase, effectively targeting rapidly proliferating tumor cells like those in choriocarcinoma. Methotrexate is highly effective as a single-agent therapy in non-metastatic or low-risk choriocarcinoma and is also part of combination regimens for high-risk disease (e.g., EMA-CO regimen: Etoposide, Methotrexate, Actinomycin-D, Cyclophosphamide, and Vincristine). Incorrect Options: (B) Actinomycin-D – Incorrect Actinomycin-D (Dactinomycin) is also used in the treatment of choriocarcinoma, particularly in patients who do not tolerate methotrexate or as part of combination therapy. It intercalates into DNA and inhibits RNA polymerase, blocking transcription. While effective, it is not the first-line drug but is often used in methotrexate-resistant cases or in combination therapy. (C) Vincristine – Incorrect Vincristine is a vinca alkaloid that inhibits microtubule polymerization, preventing mitotic spindle formation and causing M-phase arrest. It is not the primary treatment for choriocarcinoma but may be included in combination chemotherapy (e.g., EMA-CO regimen). However, it is not as effective as methotrexate for single-agent therapy. (D) 6-Thioguanine – Incorrect 6-Thioguanine is a purine analog that interferes with DNA synthesis. It is primarily used for treating acute leukemias rather than choriocarcinoma. It lacks efficacy against trophoblastic tumors and is not recommended for choriocarcinoma treatment.",
      "correct_choice_id": 258769,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43996511700320002/43996511700320002.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43996511700320002/43996511700320002.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57865,
      "choices": [
        {
          "id": 258773,
          "text": "Gynecomastia"
        },
        {
          "id": 258774,
          "text": "Riedel thyroiditis"
        },
        {
          "id": 258775,
          "text": "Ovarian cancer"
        },
        {
          "id": 258776,
          "text": "Prophylaxis of breast cancer"
        }
      ],
      "text": "Tamoxifen is useful for all except:",
      "unique_key": "Q4231114",
      "question_audio": null,
      "question_video": null,
      "map_id": 34905562,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Tamoxifen is NOT useful for ovarian cancer, making option (C) the correct answer. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue and an agonist in other tissues like the endometrium and bone. While it is a well-established drug for hormone receptor-positive breast cancer, it is not a standard treatment for ovarian cancer, as ovarian cancer is less dependent on estrogen signaling compared to breast cancer. Instead, ovarian cancer is typically treated with surgery and chemotherapy (e.g., platinum-based agents like cisplatin and carboplatin). Explanation of Incorrect Options: (A) Gynecomastia: Incorrect. Tamoxifen is useful in treating gynecomastia, especially in men undergoing androgen deprivation therapy (e.g., for prostate cancer) or experiencing hormonal imbalances. It works by blocking estrogen receptors in breast tissue, preventing estrogen-mediated breast enlargement. (B) Riedel thyroiditis: Incorrect. Riedel thyroiditis is a rare fibrosing disorder of the thyroid gland, leading to a hard, fixed thyroid mass. Tamoxifen has been found to be beneficial due to its anti-fibrotic effects, likely through its agonistic action on estrogen receptors in fibroblasts, reducing excessive fibrosis. (D) Prophylaxis of breast cancer: Incorrect. Tamoxifen is widely used for breast cancer prevention in high-risk women, particularly those with BRCA mutations or a strong family history. It reduces the risk of developing estrogen receptor-positive (ER+) breast cancer by acting as an estrogen antagonist in breast tissue.",
      "correct_choice_id": 258775,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53399881700320068/53399881700320068.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53399881700320068/53399881700320068.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57866,
      "choices": [
        {
          "id": 258777,
          "text": "Enzalutamine"
        },
        {
          "id": 258778,
          "text": "Apalutamide"
        },
        {
          "id": 258779,
          "text": "Abiraterone acetate"
        },
        {
          "id": 258780,
          "text": "Bicalutamide"
        }
      ],
      "text": "A 62 year old male patient comes to you with urinary retention, back pain, and hematuria. He also has complaints of Weight loss and loss of appetite, Bone pain with repeated fracture and Neurologic deficits. On Digital rectal examination a nodule is discovered on prostate and prostate-specific antigen (PSA) found out to be very high on evaluation. You have started first line hormonal therapy for the above problem but patient disease found to be refractory to it. Now, all of the following can be chosen for above refractory disease except :",
      "unique_key": "Q1980424",
      "question_audio": null,
      "question_video": null,
      "map_id": 34949078,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Bicalutamide, as it is not the preferred treatment for castration-resistant prostate cancer (CRPC). The patient presents with advanced metastatic prostate cancer, as indicated by urinary retention, back pain, hematuria, weight loss, bone pain with fractures, and neurologic deficits. The high PSA levels and prostate nodule further confirm the diagnosis. First-line hormonal therapy (androgen deprivation therapy, ADT) was started but failed, meaning the disease has progressed to castration-resistant prostate cancer (CRPC). Bicalutamide is a first-generation androgen receptor antagonist, which is typically used in combination with ADT but is not effective in CRPC. In contrast, newer agents like enzalutamide, apalutamide, and abiraterone acetate are preferred in CRPC. Explanation of Incorrect Options: (A) Enzalutamide: Incorrect. Enzalutamide is a potent second-generation androgen receptor inhibitor that works by blocking androgen receptor signaling at multiple levels. It is used for CRPC and provides better efficacy than bicalutamide by preventing nuclear translocation and DNA binding of the androgen receptor. (B) Apalutamide: Incorrect. Apalutamide is another second-generation androgen receptor inhibitor, similar to enzalutamide, and is effective in treating non-metastatic CRPC and metastatic hormone-sensitive prostate cancer (mHSPC). It is more potent than first-generation anti-androgens like bicalutamide. (C) Abiraterone acetate: Incorrect. Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis in the adrenal glands, testes, and tumor tissues. It is used in CRPC, often combined with prednisone to reduce mineralocorticoid side effects.",
      "correct_choice_id": 258780,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24129081700320090/24129081700320090.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24129081700320090/24129081700320090.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57867,
      "choices": [
        {
          "id": 258781,
          "text": "Methotrexate"
        },
        {
          "id": 258782,
          "text": "6-Mercaptopurine"
        },
        {
          "id": 258783,
          "text": "ifosfamide"
        },
        {
          "id": 258784,
          "text": "Cytosine arabinoside"
        }
      ],
      "text": "Defibrotide is a drug given alonwith which group of anticancer drugs to prevent toxicity:",
      "unique_key": "Q9005707",
      "question_audio": null,
      "question_video": null,
      "map_id": 34282668,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ifosfamide, as defibrotide is used to prevent and treat veno-occlusive disease (VOD), a serious complication associated with ifosfamide and other alkylating agents. Ifosfamide, a nitrogen mustard-derived alkylating agent, is used to treat various cancers but is associated with endothelial damage, hepatotoxicity, and veno-occlusive disease (VOD), particularly in high-dose chemotherapy settings like bone marrow transplantation. Defibrotide is a pro-fibrinolytic and endothelial-protective agent, which helps prevent VOD by reducing endothelial damage, enhancing fibrinolysis, and protecting microvascular integrity. Explanation of Incorrect Options: (A) Methotrexate: Incorrect. Methotrexate is a folate antagonist used in cancers like leukemia, lymphoma, and solid tumors. Its main toxicities include myelosuppression, hepatotoxicity, mucositis, and nephrotoxicity, but it is not strongly associated with VOD. Instead, leucovorin (folinic acid) is used to rescue normal cells from methotrexate toxicity. (B) 6-Mercaptopurine: Incorrect. 6-Mercaptopurine (6-MP) is a purine analog used in acute lymphoblastic leukemia (ALL). Its main toxicities include myelosuppression and hepatotoxicity, particularly when combined with allopurinol (due to xanthine oxidase inhibition). However, it does not cause VOD, and defibrotide is not typically used with it. (D) Cytosine arabinoside (Cytarabine): Incorrect. Cytarabine is a pyrimidine analog used in leukemia treatment, mainly associated with cerebellar toxicity, myelosuppression, and conjunctivitis (chemical conjunctivitis requiring steroid eye drops). It is not linked to VOD, so defibrotide is not required.",
      "correct_choice_id": 258783,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/857901700320142/857901700320142.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/857901700320142/857901700320142.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57868,
      "choices": [
        {
          "id": 258785,
          "text": "Breast"
        },
        {
          "id": 258786,
          "text": "Prostate"
        },
        {
          "id": 258787,
          "text": "Kidney"
        },
        {
          "id": 258788,
          "text": "Pancreas"
        }
      ],
      "text": "Sipuleucel-T is used in the treatment of which cancer?",
      "unique_key": "Q8500577",
      "question_audio": null,
      "question_video": null,
      "map_id": 34569749,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Prostate cancer, as Sipuleucel-T is an autologous cellular immunotherapy specifically approved for metastatic castration-resistant prostate cancer (mCRPC). It is a personalized cancer vaccine that enhances the body's immune response against prostate cancer cells. The therapy involves **collecting a patient’s dendritic cells, priming them with a recombinant fusion protein (PA2024) consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), and then reinfusing them into the patient. This process activates T cells to recognize and attack prostate cancer cells expressing PAP, thereby slowing disease progression. It is used in asymptomatic or minimally symptomatic mCRPC patients and provides a modest survival benefit. Explanation of Incorrect Options: (A) Breast cancer: Incorrect. Breast cancer is treated with hormonal therapies (e.g., tamoxifen, aromatase inhibitors), targeted therapies (trastuzumab for HER2+ cases), and chemotherapy. Sipuleucel-T has no role in breast cancer treatment. (C) Kidney cancer: Incorrect. Kidney cancer, particularly renal cell carcinoma (RCC), is treated with tyrosine kinase inhibitors (sunitinib, pazopanib), immune checkpoint inhibitors (nivolumab, pembrolizumab), and mTOR inhibitors (everolimus). Sipuleucel-T is not indicated for kidney cancer. (D) Pancreatic cancer: Incorrect. Pancreatic cancer is primarily managed with chemotherapy (gemcitabine, FOLFIRINOX), targeted therapy (erlotinib for EGFR mutations), and immunotherapy in selected cases. Sipuleucel-T is not used in its treatment.",
      "correct_choice_id": 258786,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60813261700320260/60813261700320260.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60813261700320260/60813261700320260.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57869,
      "choices": [
        {
          "id": 258789,
          "text": "Melphalan"
        },
        {
          "id": 258790,
          "text": "Thalidomide"
        },
        {
          "id": 258791,
          "text": "Bortezomib"
        },
        {
          "id": 258792,
          "text": "Methotrexate"
        }
      ],
      "text": "Which of the following drug is not used for multiple myeloma:",
      "unique_key": "Q4941254",
      "question_audio": null,
      "question_video": null,
      "map_id": 34124041,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Methotrexate, as it is not used for multiple myeloma. Methotrexate is a folate antagonist that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis, and is primarily used for leukemias, lymphomas, osteosarcoma, and autoimmune diseases (such as rheumatoid arthritis and psoriasis). Multiple myeloma (MM) is a plasma cell malignancy that requires drugs targeting proteasomes, immunomodulatory pathways, and alkylating agents. Methotrexate does not have a significant role in MM treatment. Explanation of Incorrect Options: (A) Melphalan – Correct match. Melphalan is an alkylating agent commonly used in multiple myeloma, particularly in combination with corticosteroids (e.g., Melphalan + Prednisone) or with autologous stem cell transplantation. It works by cross-linking DNA strands, leading to cell cycle arrest and apoptosis. (B) Thalidomide – Correct match. Thalidomide is an immunomodulatory drug (IMiD) that acts by inhibiting angiogenesis, modulating cytokine production, and enhancing T-cell and NK-cell function. It is used in MM, particularly in older patients who are ineligible for stem cell transplantation. However, it has severe teratogenic effects and can cause peripheral neuropathy and thromboembolism. (C) Bortezomib – Correct match. Bortezomib is a proteasome inhibitor that blocks the degradation of pro-apoptotic factors in myeloma cells, leading to cell death. It is a cornerstone of MM treatment, often used in regimens like VRd (Bortezomib, Lenalidomide, Dexamethasone). It is associated with peripheral neuropathy and thrombocytopenia as major side effects.",
      "correct_choice_id": 258792,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61148381700320287/61148381700320287.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61148381700320287/61148381700320287.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57870,
      "choices": [
        {
          "id": 258793,
          "text": "melphalan"
        },
        {
          "id": 258794,
          "text": "cisplatin"
        },
        {
          "id": 258795,
          "text": "temozolamide"
        },
        {
          "id": 258796,
          "text": "estramustine"
        }
      ],
      "text": "DOC for glioblastoma multiforme?",
      "unique_key": "Q8632683",
      "question_audio": null,
      "question_video": null,
      "map_id": 34843745,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Temozolomide, as it is the drug of choice (DOC) for glioblastoma multiforme (GBM). Glioblastoma is the most aggressive and common primary brain tumor in adults, and temozolomide (TMZ) is the first-line chemotherapeutic agent used, often in combination with radiotherapy (Stupp protocol). Temozolomide is an oral alkylating agent that methylates guanine residues in DNA, leading to DNA damage and apoptosis. Importantly, it crosses the blood-brain barrier (BBB), making it effective against brain tumors. The efficacy of temozolomide is influenced by MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation, where methylated MGMT tumors respond better due to reduced DNA repair capability. Explanation of Incorrect Options: (A) Melphalan – Incorrect. Melphalan is an alkylating agent primarily used for multiple myeloma and conditioning before stem cell transplantation. It does not effectively cross the BBB and is not the drug of choice for glioblastoma. (B) Cisplatin – Incorrect. Cisplatin is a platinum-based alkylating agent used in various cancers, such as testicular, ovarian, bladder, and lung cancers. Although it has some role in brain tumors, it has poor CNS penetration due to the blood-brain barrier, making it less effective for glioblastoma treatment. (D) Estramustine – Incorrect. Estramustine is a combination of estradiol and nitrogen mustard, mainly used for prostate cancer due to its anti-mitotic and hormonal effects. It is not used for glioblastoma and does not cross the BBB effectively.",
      "correct_choice_id": 258795,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74659471700320392/74659471700320392.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74659471700320392/74659471700320392.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57871,
      "choices": [
        {
          "id": 258797,
          "text": "6-Mercaptopurine"
        },
        {
          "id": 258798,
          "text": "Cyclophosphamide"
        },
        {
          "id": 258799,
          "text": "6-Thioguanine"
        },
        {
          "id": 258800,
          "text": "Cimetidine"
        }
      ],
      "text": "A patient receiving allopurinol requires dose reduction of :",
      "unique_key": "Q2162498",
      "question_audio": null,
      "question_video": null,
      "map_id": 34025713,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) 6-Mercaptopurine Allopurinol is a xanthine oxidase inhibitor used primarily in the treatment of hyperuricemia and gout. It reduces the metabolism of purine-based drugs that rely on xanthine oxidase for their breakdown. 6-Mercaptopurine (6-MP) is a purine analog that is metabolized by xanthine oxidase. When allopurinol is co-administered with 6-MP, it inhibits the enzyme responsible for metabolizing 6-MP, leading to increased drug levels and a higher risk of toxicity, including myelosuppression. Therefore, the dose of 6-MP must be significantly reduced (often to about one-third or one-fourth of the usual dose) when given alongside allopurinol to prevent severe adverse effects. This makes option A (6-Mercaptopurine) the correct answer. Explanation of Incorrect Options: B. Cyclophosphamide – Cyclophosphamide is an alkylating agent that does not rely on xanthine oxidase for metabolism. Instead, it is activated by liver enzymes (mainly cytochrome P450). Since allopurinol does not affect this metabolic pathway, dose adjustment of cyclophosphamide is not required. C. 6-Thioguanine – While 6-thioguanine (6-TG) is also a purine analog like 6-MP, its metabolism is less dependent on xanthine oxidase. Instead, it is primarily broken down by thiopurine methyltransferase (TPMT). Since allopurinol does not significantly inhibit TPMT, the interaction is not as clinically significant, and dose reduction is not necessarily required. D. Cimetidine – Cimetidine is a histamine H2 receptor antagonist used to reduce gastric acid secretion. It is primarily metabolized by the liver and kidneys, and its metabolism does not involve xanthine oxidase. Therefore, allopurinol does not affect cimetidine’s pharmacokinetics, making dose reduction unnecessary.",
      "correct_choice_id": 258797,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45806251700320409/45806251700320409.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45806251700320409/45806251700320409.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57872,
      "choices": [
        {
          "id": 258801,
          "text": "Exerts antiplatelet, rather than thrombotic, effects"
        },
        {
          "id": 258802,
          "text": "Lacks ability to cause hot flashes or other disturbing side effects"
        },
        {
          "id": 258803,
          "text": "Lower risk of causing endometrial cancer"
        },
        {
          "id": 258804,
          "text": "Provides clinical cure, rather than palliation, in all patients"
        }
      ],
      "text": "A 48-yrs-old post menopausal female is diagnosed with metastatic breast cancer. Why might fulvestrant be the better choice over tamoxifen provided all other factors being equal?",
      "unique_key": "Q5585017",
      "question_audio": null,
      "question_video": null,
      "map_id": 34357180,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Lower risk of causing endometrial cancer Explanation for the Correct Answer: Fulvestrant is a selective estrogen receptor degrader (SERD) that works by binding to and degrading estrogen receptors (ERs), leading to complete estrogen blockade in breast cancer cells. It is used in postmenopausal women with ER-positive metastatic breast cancer when other hormonal therapies, such as tamoxifen or aromatase inhibitors, fail. Unlike tamoxifen, which acts as a selective estrogen receptor modulator (SERM) with estrogen agonist activity on the endometrium, fulvestrant has no agonist activity anywhere in the body. Tamoxifen increases the risk of endometrial hyperplasia and carcinoma due to its partial estrogen agonist effect on the endometrium, while fulvestrant does not stimulate the endometrium, thus lowering the risk of endometrial cancer. Thus, fulvestrant is a better choice in postmenopausal women at risk of endometrial complications compared to tamoxifen. Explanation for the Incorrect Answers: (A) Exerts antiplatelet, rather than thrombotic, effects This statement is incorrect, as fulvestrant does not have antiplatelet effects. Both tamoxifen and fulvestrant have a risk of thromboembolism, but tamoxifen is associated with a higher risk of deep vein thrombosis (DVT) and pulmonary embolism due to its partial estrogen agonist activity. However, fulvestrant does not exert a significant antiplatelet effect. (B) Lacks ability to cause hot flashes or other disturbing side effects Fulvestrant can still cause hot flashes, as it leads to estrogen depletion, similar to other anti-estrogen therapies. Other side effects such as joint pain, fatigue, and injection-site reactions are also possible. However, fulvestrant does not cause as many estrogen-related side effects as tamoxifen, but it is not entirely free from them. (D) Provides clinical cure, rather than palliation, in all patients No hormonal therapy provides a \"clinical cure\" for metastatic breast cancer. Fulvestrant only provides disease control and slows progression, similar to tamoxifen and other endocrine therapies. Metastatic breast cancer remains an incurable condition, requiring palliative treatment with a focus on prolonging survival and improving quality of life.",
      "correct_choice_id": 258803,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41311801700305822/41311801700305822.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41311801700305822/41311801700305822.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57873,
      "choices": [
        {
          "id": 258805,
          "text": "Vinblastine"
        },
        {
          "id": 258806,
          "text": "Dactinomycin"
        },
        {
          "id": 258807,
          "text": "Cyclophosphamide"
        },
        {
          "id": 258808,
          "text": "6-Mercaptopurine"
        }
      ],
      "text": "A patient with cancer developed extreme degree of radiation toxicity. Further history revealed that the dose adjustment of a particular drug was missed during the course of radiotherapy. Which of the following drugs required a dose adjustment during radiotherapy in order to prevent radiation toxicity ?",
      "unique_key": "Q8224379",
      "question_audio": null,
      "question_video": null,
      "map_id": 34543323,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Dactinomycin Explanation for the Correct Answer: Dactinomycin (Actinomycin D) is a cytotoxic antibiotic that intercalates into DNA and inhibits RNA polymerase, thereby blocking transcription and leading to cell death. It is primarily used in the treatment of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, and gestational trophoblastic neoplasia. Dactinomycin is a potent radiation sensitizer, meaning it enhances the effects of radiation therapy by increasing DNA damage in irradiated tissues. If the dose of dactinomycin is not adjusted during radiotherapy, it can lead to excessive radiation toxicity, causing severe tissue damage, skin necrosis, mucositis, myelosuppression, and gastrointestinal toxicity. To prevent severe radiation toxicity, the dose of dactinomycin must be reduced or temporarily withheld during radiation therapy. Thus, dactinomycin requires dose adjustment during radiotherapy, making it the correct answer. Explanation for the Incorrect Answers: (A) Vinblastine Vinblastine is a vinca alkaloid that inhibits microtubule formation, leading to mitotic arrest. It is used to treat Hodgkin’s lymphoma, testicular cancer, and Kaposi’s sarcoma. It does not significantly enhance radiation toxicity, although it can cause myelosuppression, neuropathy, and GI disturbances. Dose adjustment during radiotherapy is not required. (C) Cyclophosphamide Cyclophosphamide is an alkylating agent that leads to DNA crosslinking and apoptosis. It is widely used for lymphomas, breast cancer, and autoimmune diseases. Although it can cause bone marrow suppression, hemorrhagic cystitis, and secondary malignancies, it does not act as a strong radiation sensitizer like dactinomycin. Dose reduction during radiotherapy is generally not required. (D) 6-Mercaptopurine (6-MP) 6-MP is a purine analog that inhibits DNA synthesis by blocking purine metabolism. It is primarily used in the treatment of acute lymphoblastic leukemia (ALL). While 6-MP requires dose adjustment when used with allopurinol (due to xanthine oxidase inhibition), it does not enhance radiation toxicity. No dose modification is necessary during radiotherapy.",
      "correct_choice_id": 258806,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8197861700306306/8197861700306306.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8197861700306306/8197861700306306.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57874,
      "choices": [
        {
          "id": 258809,
          "text": "Anthracycline"
        },
        {
          "id": 258810,
          "text": "Alkylating agent"
        },
        {
          "id": 258811,
          "text": "Platinum compound"
        },
        {
          "id": 258812,
          "text": "Bisphosphonates"
        }
      ],
      "text": "A 50 year old woman. Hema has been diagnosed with locally advanced breast cancer and recommended for chemotherapy. She has five years history of myocardial infarction and congestive heart failure. Which antineoplastic drug should be best avoided :",
      "unique_key": "Q9869705",
      "question_audio": null,
      "question_video": null,
      "map_id": 34055878,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Anthracycline Explanation for the Correct Answer: Anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin) are potent topoisomerase II inhibitors used in the treatment of various cancers, including breast cancer, lymphomas, and leukemias. However, they are well-known for their dose-dependent cardiotoxicity, which can manifest as: Acute cardiotoxicity – occurring within days of administration, leading to arrhythmias, pericarditis, and myocarditis. Chronic cardiotoxicity – presenting months to years later as dilated cardiomyopathy and congestive heart failure (CHF) due to irreversible myocardial damage. Cumulative dose-dependent toxicity – The risk increases significantly with a cumulative dose of doxorubicin > 450 mg/m². Since Hema has a history of myocardial infarction and congestive heart failure, she is already at high risk for cardiac complications. The use of anthracyclines in such patients can further worsen cardiac function, leading to life-threatening heart failure, making anthracyclines the drug class to be best avoided in her treatment. Explanation for the Incorrect Answers: (B) Alkylating agents Alkylating agents (e.g., cyclophosphamide, ifosfamide, melphalan) work by cross-linking DNA strands, leading to cell cycle arrest and apoptosis. While some alkylating agents like cyclophosphamide can cause hemorrhagic cystitis and bone marrow suppression, their cardiotoxicity is relatively rare and mostly seen at very high doses. They are not contraindicated in patients with heart disease and can be used cautiously in breast cancer treatment. (C) Platinum compounds Platinum-based drugs (cisplatin, carboplatin, oxaliplatin) act by forming DNA crosslinks and inducing apoptosis in cancer cells. These drugs are primarily associated with nephrotoxicity (cisplatin), neurotoxicity (oxaliplatin), and ototoxicity, but do not pose a significant risk of cardiotoxicity like anthracyclines. They are safer alternatives in breast cancer patients with pre-existing heart disease. (D) Bisphosphonates Bisphosphonates (zoledronic acid, pamidronate, alendronate) are used in breast cancer with bone metastases to prevent skeletal-related events (fractures, hypercalcemia, bone pain). They have no direct cardiotoxic effects and are not associated with worsening heart failure or myocardial infarction. They can be safely used in patients with cardiac conditions.",
      "correct_choice_id": 258809,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40820251700305837/40820251700305837.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40820251700305837/40820251700305837.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57875,
      "choices": [
        {
          "id": 258813,
          "text": "Enzalutamine"
        },
        {
          "id": 258814,
          "text": "Apalutamide"
        },
        {
          "id": 258815,
          "text": "Abiraterone acetate"
        },
        {
          "id": 258816,
          "text": "Bicalutamide"
        }
      ],
      "text": "A 62 year old male patient comes to you with urinary retention, back pain, and hematuria. He also has complaints of Weight loss and loss of appetite, Bone pain with repeated fracture and Neurologic deficits. On Digital rectal examination a nodule is discovered on prostate and prostate-specific antigen (PSA) found out to be very high on evaluation. You have started first line hormonal therapy for the above problem but patient disease found to be refractory to it. Now, all of the following can be chosen for above refractory disease except :",
      "unique_key": "Q7870138",
      "question_audio": null,
      "question_video": null,
      "map_id": 34663165,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Bicalutamide Explanation for the Correct Answer: Bicalutamide should not be chosen for refractory prostate cancer because it is a first-generation anti-androgen, which is primarily used in hormone-sensitive prostate cancer in combination with androgen deprivation therapy (ADT). However, in cases of castration-resistant prostate cancer (CRPC)—when the disease no longer responds to first-line hormonal therapy—bicalutamide is ineffective and often leads to resistance rather than further disease control. Mechanism of Resistance: Prostate cancer cells can develop mutations in the androgen receptor (AR), which may cause bicalutamide to act as a partial agonist rather than an antagonist, worsening the disease instead of controlling it. Newer next-generation androgen receptor inhibitors (Enzalutamide, Apalutamide) or androgen synthesis inhibitors (Abiraterone) are preferred in refractory cases. Explanation for the Incorrect Answers: (A) Enzalutamide Enzalutamide is a potent androgen receptor inhibitor used in castration-resistant prostate cancer (CRPC). Unlike bicalutamide, it effectively blocks androgen receptor signaling, preventing tumor growth even when testosterone levels are low. It is commonly used in metastatic CRPC and has shown improved survival rates. (B) Apalutamide Apalutamide is another next-generation androgen receptor inhibitor, similar to enzalutamide. It is used in non-metastatic CRPC as well as metastatic hormone-sensitive prostate cancer (mHSPC). It prevents the progression of prostate cancer that has become resistant to first-line therapy. (C) Abiraterone Acetate Abiraterone works by inhibiting CYP17, an enzyme necessary for androgen biosynthesis. This effectively reduces androgen production from all sources, including the testes, adrenal glands, and tumor itself. It is a key drug in castration-resistant prostate cancer (CRPC), especially in metastatic cases.",
      "correct_choice_id": 258816,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17524831700305995/17524831700305995.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17524831700305995/17524831700305995.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57876,
      "choices": [
        {
          "id": 258817,
          "text": "Hydroxyurea"
        },
        {
          "id": 258818,
          "text": "Aspirin"
        },
        {
          "id": 258819,
          "text": "Corticosteroids"
        },
        {
          "id": 258820,
          "text": "Transfusion of red blood cells"
        }
      ],
      "text": "A 28-year-old woman with a history of sickle cell disease presents to the emergency department with severe pain in her abdomen and joints. She is treated with intravenous hydration and opioids for pain control. Which of the following additional therapies is most appropriate for managing her pain crisis?",
      "unique_key": "Q6279661",
      "question_audio": null,
      "question_video": null,
      "map_id": 34528254,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hydroxyurea Hydroxyurea is the most appropriate additional therapy for managing pain crises in patients with sickle cell disease (SCD). It is a disease-modifying agent that works by increasing fetal hemoglobin (HbF) production, which reduces hemoglobin polymerization and sickling of red blood cells. This leads to fewer vaso-occlusive crises, reduced need for transfusions, and lower rates of acute chest syndrome. Hydroxyurea is recommended for patients with frequent vaso-occlusive crises, severe symptomatic anemia, or a history of acute chest syndrome. Although it is not an immediate treatment for an acute pain crisis, its chronic use significantly decreases the frequency and severity of pain episodes over time. Explanation of Incorrect Options: (B) Aspirin: Aspirin is not an effective treatment for vaso-occlusive pain crises in sickle cell disease. While it has anti-inflammatory and analgesic properties, it is not strong enough to manage the severe pain associated with sickle cell crises, which typically require opioids. Aspirin also does not prevent further sickling of red blood cells or reduce the frequency of crises. (C) Corticosteroids: Corticosteroids are generally avoided in sickle cell disease because they can increase the risk of rebound vaso-occlusive crises once discontinued. While steroids may reduce inflammation, they can worsen sickling by promoting leukocytosis and increasing blood viscosity. Therefore, they are not recommended for routine management of sickle cell pain crises. (D) Transfusion of red blood cells: Although red blood cell transfusions are used in specific complications of sickle cell disease, such as acute chest syndrome, stroke prevention, or severe anemia, they are not routinely used for uncomplicated vaso-occlusive pain crises. Frequent transfusions also carry risks of iron overload and alloimmunization. Therefore, transfusion is not the best additional therapy for managing a pain crisis unless there is evidence of severe anemia or other complications.",
      "correct_choice_id": 258817,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50868541727676420/50868541727676420.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50868541727676420/50868541727676420.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57877,
      "choices": [
        {
          "id": 258821,
          "text": "Treatment should be started immediately due to her diagnosis."
        },
        {
          "id": 258822,
          "text": "Watchful waiting is appropriate since she is asymptomatic."
        },
        {
          "id": 258823,
          "text": "Chemotherapy should be the first-line treatment regardless of symptoms."
        },
        {
          "id": 258824,
          "text": "Targeted therapy with a BTK inhibitor should be started right away."
        }
      ],
      "text": "A 60-year-old female with newly diagnosed chronic lymphocytic leukemia (CLL) is considering treatment options. She is asymptomatic with a normal lymphocyte count. Which of the following statements regarding the initiation of treatment is true?",
      "unique_key": "Q4518472",
      "question_audio": null,
      "question_video": null,
      "map_id": 34714721,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Watchful waiting is appropriate since she is asymptomatic. Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy that often follows a slow, asymptomatic course. Many patients are diagnosed incidentally during routine blood tests. In asymptomatic patients with a normal lymphocyte count, no cytopenias, and no significant lymphadenopathy or organ involvement, immediate treatment is not required. Instead, a \"watchful waiting\" or active surveillance approach is recommended. This involves regular monitoring with physical exams, blood counts, and imaging (if needed) to detect disease progression. Early treatment has not been shown to improve survival in asymptomatic patients, so therapy is only initiated if the patient develops symptoms such as progressive cytopenias, bulky lymphadenopathy, organ involvement, or constitutional symptoms (fever, weight loss, night sweats). Explanation of Incorrect Options: (A) Treatment should be started immediately due to her diagnosis. This statement is incorrect because treatment decisions in CLL are not based on diagnosis alone. Many patients remain stable without symptoms for years, and immediate treatment does not improve survival. Instead, treatment is only initiated when there are clear indications of disease progression or symptomatic burden. (C) Chemotherapy should be the first-line treatment regardless of symptoms. Traditional chemotherapy (e.g., fludarabine, cyclophosphamide) was once the mainstay of CLL treatment, but it is no longer the first-line approach, especially for asymptomatic patients. Chemotherapy is associated with significant toxicities, including bone marrow suppression and secondary malignancies. Furthermore, many newer targeted therapies (e.g., BTK inhibitors, BCL-2 inhibitors) have replaced chemotherapy in symptomatic patients. Since this patient is asymptomatic, no treatment—chemotherapy or otherwise—is currently needed. (D) Targeted therapy with a BTK inhibitor should be started right away. Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib) are effective targeted therapies used in symptomatic CLL, particularly in patients with high-risk mutations (e.g., del(17p), TP53 mutations). However, starting targeted therapy in an asymptomatic patient is not appropriate. These drugs are reserved for patients who show disease progression, develop significant cytopenias, or experience symptomatic lymphadenopathy/organ involvement. Unnecessary treatment exposes the patient to potential side effects, such as bleeding, atrial fibrillation, and hypertension.",
      "correct_choice_id": 258822,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31471871727676439/31471871727676439.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31471871727676439/31471871727676439.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}